Published in Am J Med Genet on December 18, 1995
Genetic counselling for schizophrenia in the era of molecular genetics. Can J Psychiatry (2001) 1.41
Categorical and dimensional aspects of co-morbidity in obsessive-compulsive disorder (OCD). Eur Child Adolesc Psychiatry (2007) 1.03
Temperamental factors in children and adolescents with obsessive-compulsive disorder (OCD) and in normal controls. Eur Child Adolesc Psychiatry (2004) 0.82
Somatization in response to undiagnosed obsessive compulsive disorder in a family. BMC Fam Pract (2003) 0.76
Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet (1999) 1.98
Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2012) 1.57
Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Arch Gen Psychiatry (2001) 1.56
Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Dig Liver Dis (2001) 1.46
[18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry (1995) 1.23
The Iowa Personality Disorder Screen: development and preliminary validation of a brief screening interview. J Pers Disord (1999) 1.17
Decision-making heterogeneity in obsessive-compulsive disorder: ventromedial prefrontal cortex function predicts different treatment outcomes. Neuropsychologia (2002) 1.15
Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol (2001) 1.09
Disorganization of anatomical connectivity in obsessive compulsive disorder: a multi-parameter diffusion tensor imaging study in a subpopulation of patients. Neurobiol Dis (2009) 1.05
Potential toxicity of mitomycin C. Arch Ophthalmol (1991) 1.04
Sensitivity to 35% CO2 in healthy first-degree relatives of patients with panic disorder. Am J Psychiatry (1995) 1.02
The cooccurrence of DSM-III-R personality disorders. J Pers Disord (1998) 1.01
Complex segregation analysis for obsessive compulsive disorder and related disorders. Am J Med Genet (1999) 0.98
Age at onset of panic disorder: influence of familial liability to the disease and of childhood separation anxiety disorder. Am J Psychiatry (1995) 0.96
Factors associated with non-participation of women in a breast cancer screening programme in a town in northern Italy. J Epidemiol Community Health (1991) 0.94
Temperament dimensions explain the comorbidity of psychiatric disorders. Compr Psychiatry (1996) 0.94
Serotonin transporter linked polymorphic region in anorexia nervosa and bulimia nervosa. Mol Psychiatry (2000) 0.93
The unipolar-bipolar dichotomy and the response to sleep deprivation. Psychiatry Res (1998) 0.93
First-cycle REM density in never-depressed subjects with borderline personality disorder. Biol Psychiatry (1999) 0.93
Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol Psychiatry (1997) 0.92
Hypersensitivity to inhalation of carbon dioxide and panic attacks. Psychiatry Res (1995) 0.90
Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment. Eur Neuropsychopharmacol (1997) 0.88
Ambulatory polysomnography of never-depressed borderline subjects: a high-risk approach to rapid eye movement latency. Biol Psychiatry (1993) 0.87
An experimental test of new theoretical models for the electrokinetic properties of biological membranes. The effect of UO2++ and tetracaine on the electrophoretic mobility of bilayer membranes and human erythrocytes. J Gen Physiol (1986) 0.87
Family history of panic disorder and hypersensitivity to CO2 in patients with panic disorder. Am J Psychiatry (1996) 0.87
A family study of schizotypal disorder. Schizophr Bull (1995) 0.86
Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. Psychiatr Genet (1997) 0.86
Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol (1998) 0.86
Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter (2007) 0.86
Asthma and panic attacks. Biol Psychiatry (1997) 0.86
The 5-HT(2A) -1438G/A polymorphism in anorexia nervosa: a combined analysis of 316 trios from six European centres. Mol Psychiatry (2002) 0.85
Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology (2001) 0.85
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J (2002) 0.85
An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette's syndrome. Psychiatry Res (2000) 0.85
Plasma interleukin-1 beta concentrations in panic disorder. Psychiatry Res (1994) 0.85
Laboratory response of patients with panic and obsessive-compulsive disorders to 35% CO2 challenges. Am J Psychiatry (1995) 0.84
Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry (2004) 0.84
Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrinology (1995) 0.84
Panic disorder: the role of the balance system. J Psychiatr Res (2001) 0.84
Vestibular testing in patients with panic disorder and chronic dizziness. Acta Otorhinolaryngol Ital (2007) 0.84
Physiological and behavioral responses to minor stressors in offspring of patients with panic disorder. J Psychiatr Res (1997) 0.83
Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry (1996) 0.83
Complex segregation analysis of obsessive-compulsive disorder in 141 families of eating disorder probands, with and without obsessive-compulsive disorder. Am J Med Genet (2000) 0.83
Frontal lobe dysfunction in schizophrenia and obsessive-compulsive disorder: a neuropsychological study. Brain Cogn (1995) 0.83
EEG power modifications in panic disorder during a temporolimbic activation task: relationships with temporal lobe clinical symptomatology. J Neuropsychiatry Clin Neurosci (1993) 0.83
A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry (2001) 0.82
Carbon dioxide/oxygen challenge test in panic disorder. Psychiatry Res (1994) 0.82
Combined family trio and case-control analysis of the COMT Val158Met polymorphism in European patients with anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet (2004) 0.81
Frontal lobe dysfunction in obsessive-compulsive disorder and major depression: a clinical-neuropsychological study. Psychiatry Res (1998) 0.81
Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol (1997) 0.81
5HT2C CYS23/SER23 polymorphism is not associated with obsessive-compulsive disorder. Psychiatry Res (1998) 0.81
Menstrual cycle-related sensitivity to 35% CO2 in panic patients. Biol Psychiatry (1995) 0.81
The 35% CO2 challenge test in patients with social phobia. Psychiatry Res (1997) 0.81
Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. Psychiatry Res (1999) 0.81
Neurocognitive functioning in bulimia nervosa: the role of neuroendocrine, personality and clinical aspects. Psychol Med (2010) 0.80
MHPG, amitriptyline and affective disorders. A longitudinal study. Int Pharmacopsychiatry (1976) 0.80
Simultaneous determination of clomipramine and its desmethyl and hydroxy metabolites in plasma of patients by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.80
Panic attacks: a twin study. Psychiatry Res (1997) 0.80
Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol Psychiatry (1999) 0.80
Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol (1997) 0.80
Personality features related to generalized anxiety disorder. Compr Psychiatry (1990) 0.80
Dizziness, migrainous vertigo and psychiatric disorders. J Laryngol Otol (2009) 0.79
Alpha reactivity in schizophrenia and in schizophrenic spectrum disorders: demographic, clinical and hemispheric assessment. Int J Psychophysiol (1989) 0.79
Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. J Clin Psychiatry (1999) 0.79
Relationship between obsessive-compulsive personality disorder and obsessive-compulsive disorder. Compr Psychiatry (1997) 0.79
The HLA system and the clinical response to treatment with chlorpromazine. Br J Psychiatry (1976) 0.79
Lack of association between obsessive-compulsive disorder and the dopamine D3 receptor gene: some preliminary considerations. Am J Med Genet (1994) 0.79
Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation. Biol Psychiatry (1997) 0.79
Follow-up of obsessive-compulsive patients treated with proserotonergic agents. J Clin Psychopharmacol (1995) 0.78
Human nuclear transcription factor gene CREM: genomic organization, mutation screening, and association analysis in panic disorder. Am J Med Genet B Neuropsychiatr Genet (2003) 0.78
Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. Psychoneuroendocrinology (1995) 0.78
A neural network approach to the outcome definition on first treatment with sertraline in a psychiatric population. Artif Intell Med (2001) 0.78
Cardiac autonomic function during sleep of never-depressed borderline subjects: a pilot study. J Psychiatr Res (1996) 0.78
A psychometric-genetic study of schizotypal disorder. Schizophr Res (1999) 0.78
Psychiatric disorders in the families of schizotypal subjects. Schizophr Bull (1991) 0.78
A neuropsychological study of dissociation in cortical and subcortical functioning in obsessive-compulsive disorder by Tower of Hanoi task. Brain Cogn (2001) 0.78
An investigation of the co-occurrence of panic and somatization disorders through temperamental variables. Psychosom Med (1999) 0.78
The structure of DSM-III-R schizotypal personality disorder diagnosed by direct interviews. Schizophr Bull (1997) 0.78
Assessment of parent-of-origin effect in families unlineally affected with panic disorder-agoraphobia. J Psychiatr Res (1999) 0.77
EEG power modifications in obsessive-compulsive disorder during olfactory stimulation. Biol Psychiatry (1996) 0.77
DSM-III-R personality disorders in panic and obsessive-compulsive disorder: a comparison study. Compr Psychiatry (1992) 0.77
Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs (2004) 0.77
Neurotransmitter and hormonal background of hostility in anorexia nervosa. Neuropsychobiology (2001) 0.77
The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. J Clin Psychopharmacol (2001) 0.77
Abnormal pattern of cortical activation associated with voluntary movement in obsessive-compulsive disorder: an EEG study. Am J Psychiatry (2001) 0.77
Subclinical impairment of lung airways in patients with panic disorder. Biol Psychiatry (1994) 0.77
A long-term prospective evaluation of first-degree relatives of panic patients who underwent the 35% CO2 challenge. Biol Psychiatry (1999) 0.77
Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol (1997) 0.77
Anticipation of age at onset in panic disorder. Am J Psychiatry (1998) 0.77
Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiology (1992) 0.77
Polymorphic MAO-A and 5-HT-transporter genes: analysis of interactions in panic disorder. World J Biol Psychiatry (2000) 0.77
Increased concentrations of various amino acids in schizophrenic patients. Evidence for heterozygosity effects? Hum Genet (1987) 0.77
Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment. Biol Psychiatry (1995) 0.76
Combined measure of smooth pursuit eye movements and ventricle-brain ratio in schizophrenic disorders. Psychiatry Res (1987) 0.76
Pharmacologic effect of toloxatone on reactivity to the 35% carbon dioxide challenge: a single-blind, random, placebo-controlled study. J Clin Psychopharmacol (1994) 0.76
Familial risks and reproductive fitness in schizophrenia. Schizophr Bull (1996) 0.76
Comorbidity of panic and somatization disorder: a genetic-epidemiological approach. Compr Psychiatry (1996) 0.76
Family study of schizophrenia: exploratory analysis for relevant factors. Schizophr Bull (1986) 0.76